GF/B22/DP11
Approved by the Board on: 15 December 2010
Expediting transition to fixed-dose combinations of artemisinin-based combination therapies (ACTs)
The Board notes that World Health Organisation (WHO) guidance[1] states that fixed-dose combination formulations (FDCs) of artemisinin-based combination therapies (ACTs) are strongly preferred to co-blistered formulations.
The Board requests the Market Dynamics and Commodities Ad-hoc Committee (MDC) to present recommendations to the Board at the Twenty-Third Board Meeting regarding appropriate transition by recipients of Global Fund financing to the use of FDCs of ACTs.
The Board also requests the MDC to analyze additional measures to accelerate the transition to FDCs of HIV/AIDS and tuberculosis medicines and to present its recommendations to the Board at its Twenty-Fourth Meeting.
[1] WHO Guidelines for the Treatment of Malaria Second Edition (2010). http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf